A Diabetes Study to Treat A Population Previously Not at Target (ADAPT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00747149
First received: September 2, 2008
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step after 6 weeks of therapy in type 2 diabetic patients previously treated with another statin and not at LDL-C targets.


Condition Intervention Phase
Type 2 Diabetes
Drug: Rosuvastatin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: 12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    The number of subjects achieving Canadian Low density lipoprotein cholesterol (LDL-C) target goals (i.e. LDL-C ≤ 2.0 mmol/L) over the total number subjects treated after 12 weeks of rosuvastatin therapy multiplied by 100


Secondary Outcome Measures:
  • Percentage of Subjects Achieving Total Cholesterol (TC)/ High-density Lipoprotein Cholesterol (HDLC) Ratio (i.e. TC/HDL < 4.0 mmol/L) at 6 and 12 Weeks of Treatment [ Time Frame: 6 and 12 Weeks ] [ Designated as safety issue: No ]
    Proportion of subjects achieving total cholesterol (TC)/ High-density lipoprotein cholesterol (HDLC) ratio (i.e. TC/HDL < 4.0 mmol/L) at 6 and 12 weeks of treatment

  • Mean Percent Change in Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDLC) , TC/HDL-C Ratio, Non-HDL-C, Triglycerides and Apolipoprotein B (ApoB) /Apolipoprotein A1 (ApoA-1) Ratio [ Time Frame: 6 and 12 Weeks ] [ Designated as safety issue: No ]
  • Mean High Sensitivity C-reactive Protein (hsCRP) Value at Week 6 and 12 [ Time Frame: 6 and 12 Weeks ] [ Designated as safety issue: No ]
  • Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy [ Time Frame: 6 and 12 Weeks ] [ Designated as safety issue: No ]

Enrollment: 598
Study Start Date: May 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin 1
titrated
Drug: Rosuvastatin
Oral
Other Name: Crestor
Experimental: Rosuvastatin 2
Non-titrated
Drug: Rosuvastatin
Oral
Other Name: Crestor

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Type 2 diabetes
  • Previously treated with a commonly accepted start dose of a statin for the last 4 weeks prior to study entry
  • Fasting LDL-C concentration of > 2.0 mmol/L (and ≤ 5.0 mmol/L) (in the past 3 months)
  • History of serum TG level of ≤ 4.6 mmol/l (in the past 3 months)

Exclusion Criteria:

  • If currently receiving therapy with any statin at a dose higher than listed
  • Rosuvastatin (current use)
  • Fibrates, niacin or resins that was not discontinued a minimum of 2 months prior to enrolment.
  • Type 1 diabetes; glycated haemoglobin (HbA1c) > 9.0%
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 1.5 × upper limit of normal (ULN) (in the past 2 months)
  • Resting diastolic or systolic blood pressure of > 95 mmHg or > 180 mmHg, respectively (in the past 2 months)
  • Unexplained serum creatine kinase (CK) level > 3 × ULN (in the past 2 months).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00747149

  Hide Study Locations
Locations
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Red Deer, Alberta, Canada
Research Site
Spruce Grove, Alberta, Canada
Research Site
St Albert, Alberta, Canada
Canada, British Columbia
Research Site
Chilliwack, British Columbia, Canada
Research Site
Coquitlam, British Columbia, Canada
Research Site
Delta, British Columbia, Canada
Research Site
Kelowna, British Columbia, Canada
Research Site
Maple Ridge, British Columbia, Canada
Research Site
Penticton, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Canada, Manitoba
Research Site
Portage La Prairie, Manitoba, Canada
Research Site
Winnipeg, Manitoba, Canada
Canada, New Brunswick
Research Site
Bathurst, New Brunswick, Canada
Research Site
Woodstock, New Brunswick, Canada
Canada, Newfoundland and Labrador
Research Site
Carbonear, Newfoundland and Labrador, Canada
Research Site
Mount Pearl, Newfoundland and Labrador, Canada
Research Site
St John's, Newfoundland and Labrador, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Research Site
Kentville, Nova Scotia, Canada
Research Site
Pubnico, Nova Scotia, Canada
Research Site
Sydney Mines, Nova Scotia, Canada
Research Site
Truro, Nova Scotia, Canada
Canada, Ontario
Research Site
Aylmer, Ontario, Canada
Research Site
Bolton, Ontario, Canada
Research Site
Chatham, Ontario, Canada
Research Site
Fort Erie, Ontario, Canada
Research Site
Georgetown, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Kitchener, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Morrisburg, Ontario, Canada
Research Site
Nepean, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Scaborough, Ontario, Canada
Research Site
Scarborough, Ontario, Canada
Research Site
Smith Falls, Ontario, Canada
Research Site
St Catherines, Ontario, Canada
Research Site
St. Catharines, Ontario, Canada
Research Site
Sudbury, Ontario, Canada
Research Site
Thornhill, Ontario, Canada
Research Site
Thorold, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Welland, Ontario, Canada
Research Site
Willowdale, Ontario, Canada
Research Site
Windsor, Ontario, Canada
Research Site
Woodstock, Ontario, Canada
Canada, Prince Edward Island
Research Site
Charlottetown, Prince Edward Island, Canada
Research Site
Kensington, Prince Edward Island, Canada
Research Site
Montague, Prince Edward Island, Canada
Canada, Quebec
Research Site
Anjou, Quebec, Canada
Research Site
Dolbeau-mistassini, Quebec, Canada
Research Site
Drummondville, Quebec, Canada
Research Site
Forestville, Quebec, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Joliette, Quebec, Canada
Research Site
L'ile- Perrot, Quebec, Canada
Research Site
La Sarre, Quebec, Canada
Research Site
Laval, Quebec, Canada
Research Site
Longueuil, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Roberval, Quebec, Canada
Research Site
Roxton Pond, Quebec, Canada
Research Site
Saint-bruno-lac-saint-jean, Quebec, Canada
Research Site
Saint-charles-borromee, Quebec, Canada
Research Site
Saint-leonard, Quebec, Canada
Research Site
Saint-marc-des-carrieres, Quebec, Canada
Research Site
Saint-pie, Quebec, Canada
Research Site
Sainte Gedeon-de-beauce, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Thetford Mines, Quebec, Canada
Research Site
Trois-rivieres, Quebec, Canada
Canada, Saskatchewan
Research Site
Moose Jaw, Saskatchewan, Canada
Research Site
Porcupine Plain, Saskatchewan, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Research Site
Yorkton, Saskatchewan, Canada
Canada
Research Site
Quebec, Canada
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Davide Meani AstraZeneca
Principal Investigator: David Lau, MD Private Practice
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00747149     History of Changes
Other Study ID Numbers: D3560L00072
Study First Received: September 2, 2008
Results First Received: August 6, 2010
Last Updated: August 29, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by AstraZeneca:
diabetes
type 2

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 01, 2014